{"id":"W2979762052","doi":"10.1182/blood.v118.21.3715.3715","title":"An Open-Label, Phase I Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with Relapsed/Refractory CD22-Positive B-Cell Non-Hodgkin Lymphoma,","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Rituximab; Tolerability; Calicheamicin; Internal medicine; Refractory (planetary science); Regimen; Febrile neutropenia; Gastroenterology; Chemotherapy regimen; Vincristine; Cyclophosphamide; Phases of clinical research; Lymphoma; Chemotherapy; Oncology; Neutropenia; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001413312,0.001462519,0.002600353,0.0005072663,0.0005036862,0.001185928,0.00114718,0.001219606,0.002348507],"category_scores_gemma":[0.0009797688,0.0007215617,0.001170972,0.0004463222,0.001309989,0.001270011,0.0003939226,0.003629037,0.0008618023],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009845893,"about_ca_system_score_gemma":0.001525673,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008103935,"about_ca_topic_score_gemma":0.002298132,"domain_scores_codex":[0.9994585,0.0002453864,0.00002602101,0.0001246656,0.00004607952,0.00009935226],"domain_scores_gemma":[0.999244,0.000127245,0.0001125057,0.00008497716,0.00004710834,0.0003843498],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6552766,0.1751963,0.006652241,0.00112002,0.001856702,0.0004295648,0.0006376079,0.002360825,0.05499619,0.0003265983,0.003026423,0.09812093],"study_design_scores_gemma":[0.4439799,0.540143,0.009038732,0.00002978881,0.000465997,0.0002084502,0.0000827168,0.001130774,0.002933457,0.0001388654,0.001818122,0.00003021455],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941285,0.001569687,0.0004744752,0.0002253038,0.0001093086,0.001780548,0.0004787971,0.00008326946,0.001150136],"genre_scores_gemma":[0.9929144,0.001078765,0.001239214,0.0004571074,0.0001888621,0.00199139,0.0009069144,0.00002535257,0.001197876],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002600353,"threshold_uncertainty_score":0.007856548,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01756875012756951,"score_gpt":0.2685898187690278,"score_spread":0.2510210686414583,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}